Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 8, Issue 9, 2014, Pages 956-963

  Ananthakrishnan, Ashwin N ^a,b   Cagan, Andrew ^d   Gainer, Vivian S ^d   Cheng, Su Chun ^c   Cai, Tianxi ^c   Szolovits, Peter ^f   Shaw, Stanley Y ^a,b   Churchill, Susanne ^g   Karlson, Elizabeth W ^b,g   Murphy, Shawn N ^a,b,d   Kohane, Isaac ^b,e,g   Liao, Katherine P ^b,g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d PARTNERS HEALTHCARE   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; ; Colorectal cancer; Crohn's disease; ; Sclerosing cholangitis; ; Ulcerative colitis;

Indexed keywords

ALKALINE PHOSPHATASE; URSODEOXYCHOLIC ACID;

ADULT; ALGORITHM; ARTICLE; BILE DUCT CARCINOMA; CLASSIFICATION ALGORITHM; COHORT ANALYSIS; COLORECTAL CANCER; CROHN DISEASE; DIGESTIVE SYSTEM CANCER; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; ICD-9-CM; INFLAMMATORY BOWEL DISEASE; INTESTINE CANCER; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NATURAL LANGUAGE PROCESSING; PANCREAS CANCER; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RANDOM SAMPLE; SCLEROSING CHOLANGITIS; SOCIAL SECURITY; TERTIARY CARE CENTER; ULCERATIVE COLITIS; CHOLANGITIS, SCLEROSING; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TRENDS; UNITED STATES; CANCER RISK; OUTCOME ASSESSMENT;

ADULT; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; DISEASE PROGRESSION; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MASSACHUSETTS; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 84906790618     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.01.019     Document Type: Article

References (44)

1. Jess T., Frisch M., Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013, 11:43-48.
2. Romberg-Camps M., Kuiper E., Schouten L., Kester A., Hesselink-van de Kruijs M., Limonard C., et al. Mortality in inflammatory bowel disease in the Netherlands 1991-2002: results of a population-based study: the IBD South-Limburg cohort. Inflamm Bowel Dis 2010, 16:1397-1410.
3. Selinger C.P., Andrews J., Dent O.F., Norton I., Jones B., McDonald C., et al. Cause-specific mortality and 30-year relative survival of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2013, 19:1880-1888.
4. Selinger C.P., Leong R.W. Mortality from inflammatory bowel diseases. Inflamm Bowel Dis 2012, 18:1566-1572.
5. Kappelman M.D., Farkas D.K., Long M.D., Erichsen R., Sandler R.S., Sorensen H.T., et al. Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Nationwide Population-based Cohort Study With 30 Years of Follow-up Evaluation. Clin Gastroenterol Hepatol 2014, 122(2):265-273.
6. Jess T., Horvath-Puho E., Fallingborg J., Rasmussen H.H., Jacobsen B.A. Cancer Risk in Inflammatory Bowel Disease According to Patient Phenotype and Treatment: A Danish Population-Based Cohort Study. Am J Gastroenterol 2013, 108(12):1869-1876.
7. Pedersen N., Duricova D., Elkjaer M., Gamborg M., Munkholm P., Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010, 105:1480-1487.
8. Boonstra K., van Erpecum K.J., van Nieuwkerk K.M., Drenth J.P., Poen A.C., Witteman B.J., et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:2270-2276.
9. Loftus E.V., Harewood G.C., Loftus C.G., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.
10. Navaneethan U., P.G.K.V, Lashner B.A., Lopez R., Kiran R.P., Shen B. Severity of primary sclerosing cholangitis and its impact on the clinical outcome of Crohn's disease. J Crohns Colitis 2012, 6:674-680.
11. Navaneethan U., Venkatesh P.G., Mukewar S., Lashner B.A., Remzi F.H., McCullough A.J., et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012, 10:540-546.
12. Garioud A., Seksik P., Chretien Y., Corphechot C., Poupon R., Poupon R.E., et al. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur J Gastroenterol Hepatol 2010, 22:842-847.
13. Torres J., Pineton de Chambrun G., Itzkowitz S., Sachar D.B., Colombel J.F. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011, 34:497-508.
14. Molodecky N.A., Myers R.P., Barkema H.W., Quan H., Kaplan G.G. Validity of administrative data for the diagnosis of primary sclerosing cholangitis: a population-based study. Liver Int 2011, 31:712-720.
15. Ananthakrishnan A.N., Cai T., Savova G., Cheng S.C., Chen P., Perez R.G., et al. Improving case definition of Crohn's disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach. Inflamm Bowel Dis 2013, 19:1411-1420.
16. Ananthakrishnan A.N., Cagan A., Gainer V.S., Cai T., Cheng S.C., Savova G., et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis 2013, 19:1921-1927.
17. Ananthakrishnan A.N., Cheng S.C., Cai T., Cagan A., Gainer V.S., Szolovits P., et al. Association Between Reduced Plasma 25-hydroxy Vitamin D and Increased Risk of Cancer in Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2013, (iOct 23. pii: S1542-3565(13)01644-3).
18. Ananthakrishnan A.N., Gainer V.S., Perez R.G., Cai T., Cheng S.C., Savova G., et al. Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease. Aliment Pharmacol Ther 2013, 37:445-454.
19. Chapman R., Fevery J., Kalloo A., Nagorney D.M., Boberg K.M., Shneider B., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51:660-678.
20. Singh S., Talwalkar J.A. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol 2013, 11:898-907.
21. Bernstein C.N., Blanchard J.F., Kliewer E., Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 91:854-862.
22. Mercer L.K., Davies R., Galloway J.B., Low A., Lunt M., Dixon W.G., et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 2013, 52:91-98.
23. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165:2337-2344.
24. Colaci M., Giuggioli D., Vacchi C., Lumetti F., Iachetta F., Marcheselli L., et al. Breast cancer in systemic sclerosis: Results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmun Rev 2014, 13(2):132-137.
25. Ngu J.H., Gearry R.B., Frampton C.M., Stedman C.A. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012, 55:522-529.
26. Card T.R., Solaymani-Dodaran M., West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol 2008, 48:939-944.
27. de Valle M.B., Bjornsson E., Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012, 32:441-448.
28. Bergquist A., Ekbom A., Olsson R., Kornfeldt D., Loof L., Danielsson A., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321-327.
29. Claessen M.M., Vleggaar F.P., Tytgat K.M., Siersema P.D., van Buuren H.R. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009, 50:158-164.
30. Wiesner R.H., Grambsch P.M., Dickson E.R., Ludwig J., MacCarty R.L., Hunter E.B., et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989, 10:430-436.
31. Kim W.R., Therneau T.M., Wiesner R.H., Poterucha J.J., Benson J.T., Malinchoc M., et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000, 75:688-694.
32. Talwalkar J.A., Lindor K.D. Natural history and prognostic models in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001, 15:563-575.
33. Dickson E.R., Murtaugh P.A., Wiesner R.H., Grambsch P.M., Fleming T.R., Ludwig J., et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992, 103:1893-1901.
34. Carroll R.J., Thompson W.K., Eyler A.E., Mandelin A.M., Cai T., Zink R.M., et al. Portability of an algorithm to identify rheumatoid arthritis in electronic health records. J Am Med Inform Assoc 2012, 19:e162-e169.
35. Kurreeman F., Liao K., Chibnik L., Hickey B., Stahl E., Gainer V., et al. Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. Am J Hum Genet 2011, 88:57-69.
36. Kho A.N., Pacheco J.A., Peissig P.L., Rasmussen L., Newton K.M., Weston N., et al. Electronic medical records for genetic research: results of the eMERGE consortium. Sci Transl Med 2011, 3:79re1.
37. McCarty C.A., Chisholm R.L., Chute C.G., Kullo I.J., Jarvik G.P., Larson E.B., et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics 2011, 4:13.
38. Fullerton S.M., Wolf W.A., Brothers K.B., Clayton E.W., Crawford D.C., Denny J.C., et al. Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet Med 2012, 14:424-431.
39. Gottesman O., Kuivaniemi H., Tromp G., Faucett W.A., Li R., Manolio T.A., et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med 2013, 15:761-771.
40. Liao K.P., Diogo D., Cui J., Cai T., Okada Y., Gainer V.S., et al. Association between low density lipoprotein and rheumatoid arthritis genetic factors with low density lipoprotein levels in rheumatoid arthritis and non-rheumatoid arthritis controls. Ann Rheum Dis 2013, [May 28, Epub ahead of print].
41. Liao K.P., Kurreeman F., Li G., Duclos G., Murphy S., Guzman R., et al. Associations of autoantibodies, autoimmune risk alleles, and clinical diagnoses from the electronic medical records in rheumatoid arthritis cases and non-rheumatoid arthritis controls. Arthritis Rheum 2013, 65:571-581.
42. Fullerton S.M., Wolf W.A., Brothers K.B., et al. Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet Med 2012, 14:424-431.
43. Gottesman O., Kuivaniemi H., Tromp G., et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med 2013, 15:761-771.
44. Liao K.P., Kurreeman F., Li G., et al. Associations of autoantibodies, autoimmune risk alleles, and clinical diagnoses from the electronic medical records in rheumatoid arthritis cases and non-rheumatoid arthritis controls. Arthritis Rheum 2013, 65:571-581.